Overview
PDSB market data
Price History
PDSB price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.74 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.50 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.23 – $1.55 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $40.1M · P/B 4.55.
Company News
8-K filing — PDS Biotechnology Corp (PDSB)SEC EDGAR · Aug 14, 2026, 12:00 PM
HC Wainwright & Co. Maintains Buy on PDS Biotechnology, Lowers Price Target to $7Benzinga · Aug 13, 2026, 4:17 PM
PDS Biotechnology Q2 EPS $(0.18) Misses $(0.13) EstimateBenzinga · Aug 13, 2026, 1:06 PM
PDS Biotechnology Stock Crashes, Strategic Refocus Pivots to Metastatic Colorectal Cancer ProgramBenzinga · Aug 11, 2026, 5:49 PM
12 Health Care Stocks Moving In Tuesday's Intraday SessionBenzinga · Aug 11, 2026, 5:06 PM
PDS Biotechnology shares are trading lower after the company issued CEO letter outlining plans to advance PDS0301 and pursue partnerships for PDS0101 after ceasing internal investment in its Phase 3 study.Benzinga · Aug 11, 2026, 2:50 PM
PDS Biotechnology Announces Strategic Refocus To Prioritize PDS0301 In Metastatic Colorectal Cancer; Expects To Advance PDS0301 Through Randomized Phase 2B Development Program Over Next 18 To 24 MonthsBenzinga · Aug 11, 2026, 12:28 PM
Correction: Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsightGlobenewswire Inc · Jul 21, 2026, 6:30 PM
Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsightGlobenewswire Inc · Jul 13, 2026, 5:15 PM
PDS Biotechnology Establishes Up To $50M At-The-Market Common Stock Offering ProgramBenzinga · Jun 15, 2026, 8:45 PM